Results 31 to 40 of about 372,006 (379)

P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis

Journal of the Formosan Medical Association, 2022
Background/Purpose: Antiplatelet therapy is the cornerstone for acute ischemic stroke or transient ischemic attack (TIA). The purpose of this study was to conduct a meta-analysis to assess the efficacy and safety of P2Y12 receptor inhibitor plus aspirin ...
Wen-Yi Huang, Bruce Ovbiagele, Meng Lee
doaj  

Anti-cancer effects and mechanism of actions of aspirin analogues in the treatment of glioma cancer [PDF]

, 2012
INTRODUCTION: In the past 25 years only modest advancements in glioma treatment have been made, with patient prognosis and median survival time following diagnosis only increasing from 3 to 7 months.
A. A. Hill, A. Altinkaya, A. Baborie, A. Bahl, A. Brodbelt, A. Brodbelt, A. Brodbelt, A. Brodbelt, A. Chalmers, A. Dubocq, A. Eason, A. Elmahdi, A. Frary, A. Frary, A. Gerhard, A. Gullan, A. Hajitou, A. J. Frary, A. Jackson, A. James, A. James, A. Joannides, A. Kia, A. Niranjan, A. O'Brien, A. Shaw, A. Shenoy, A. Shivane, A. Shoakazemi, A. Singh, A. Singleton, A. Sofat, A. Sottoriva, A. Williamson, A. Young, A. Young, B. Hacking, B. Harding, B. Haylock, B. Haylock, B. Haylock, B. Herron, C. Chatelain, C. Crosby, C. Davis, C. Hanemann, C. L. Nigro, C. Lawrence, C. O. Hanemann, C. Romanowski, C. Schmidberger, C. Walker, C. Walker, C. Walker, C. Watts, C. Watts, C. Watts, D. A. Jellinek, D. Bowyer, D. Cavers, D. Conkey, D. Coope, D. Crooks, D. Crooks, D. Crooks, D. du Plessis, D. Elder, D. G. O'Donovan, D. Husband, D. J. Coope, D. Kondziolka, D. Parkinson, D. Sheer, D. Thompson, D. W. Ellison, E. A. Chiocca, E. Clarke, E. Ercolano, E. Goessl, E. Hatzimichael, E. Healy, E. McGrath, E. Murray, F. Harris, F. McKevitt, F. Roncaroli, F. Roncaroli, F. Rowther, F. Rowther, F. Rowther, F. Turkheimer, G. Cruickshank, G. Hall, G. Hall, G. J. Pilkington, G. J. Pilkington, G. Pilkington, G. Pilkington, G. Pilkington, G. Pilkington, G. Thompson, G. Wall, G. Zilidis, H. Coley, H. Dogra, H. Kano, H. Kardooni, H. Wong, I. C. Morley, I. Corbett, I. Craven, I. Nicholl, I. Noorani, I. Qaddoumi, I. R. Whittle, I. Spiteri, J. Alder, J. Baily, J. Bambrough, J. Bambrough, J. Bomalaski, J. Darling, J. Darling, J. Darling, J. Darling, J. Darling, J. Dunn, J. Dunn, J. Harney, J. Holliday, J. Ironside, J. Larsen, J. Leggate, J. Logan, J. M. Przystal, J. N. Jeyapalan, J. Simpson, J. Singh, J. Tavare, K. Ashkan, K. Ashkan, K. Ashton, K. Ashton, K. Ashton, K. Chen, K. Das, K. E. Hatherell, K. Herholz, K. Hopkins, K. Hopkins, K. Janczar, K. Karabatsou, K. Karabatsou, K. Karakoula, K. Karakoula, K. Kroese, K. M. Kurian, K. M. Kurian, K. M. Kurian, K. M. Prise, K. McCarthy, K. O'Neil, K. Phipps, K. Prise, L. Brazil, L. Donovan, L. Evans, L. Lattanzio, L. Lunsford, L. Mohsen, L. Rada, L. Shaw, L. Spinelli, L. Steele, L. Taggart, L. Wallace, L. Zhou, M. A. Mumin, M. Altinkaya, M. Anand, M. Anand, M. Arora, M. Barczyk, M. Boissinot, M. Bradley, M. C. Schmid, M. Diaz, M. Donnelly, M. Frame, M. Jenkinson, M. Jenkinson, M. Jenkinson, M. Keeling, M. Mackinnon, M. McLean, M. Morris, M. R. Morris, M. Williams, N. A. Pullen, N. A. Pullen, N. Burnet, N. Cohen, N. D. Mazarakis, N. Hoggard, N. Marko, N. Nianiaris, N. Potter, N. R. Leslie, N. Rathi, N. Rathi, N. Syed, O. Sansom, O. Thomas, P. Brennan, P. Collins, P. Grundy, P. J. Mintz, P. Metherall, P. Singh, P. Singh, P. Szlosarek, P. Tibarewal, P. Welsby, Q. An, R. Beaney, R. Bhangoo, R. Blake, R. Brock, R. G. Tatevossian, R. Grundy, R. Hamilton, R. Hayward, R. Hinz, R. Jackson, R. Jena, R. Lea, R. McConnell, R. Muirhead, R. P. Pangeni, R. Rahman, S. Al-Rashid, S. Ammoun, S. Ammoun, S. Bell, S. Bell, S. Birks, S. Birks, S. Birks, S. Birks, S. Green, S. Hafizi, S. Hafizi, S. Higgins, S. J. Price, S. J. Price, S. J. Price, S. Jefferies, S. Kokkinos, S. Lawler, S. Leow-Dyke, S. Leow-Dyke, S. Leow-Dyke, S. Mashal, S. McQuaid, S. Price, S. Price, S. Price, S. Price, S. Saini, S. Scott, S. Shepherd, S. Smith, S. T. Al Rashid, S. Tavare, S. Wilkins, S. Williams, S. Williams, T. Crook, T. Dawson, T. Dawson, T. Dawson, T. Flannery, T. Flannery, T. Gaissmaier, T. J. Warr, T. Jacques, T. Jaunky, T. Lawson, T. Smith, T. Van Meter, T. Warr, T. Warr, T. Warr, T. Warr, T. Warr, V. Beckett, V. Berry, V. Bosak, V. Brunton, V. Hurwitz, V. Iyer, V. Iyer, V. Lupson, V. Petinou, W. Harkness, W. Stewart, W. Stewart, Y. Majani, Y. Zhang, Z. Hanzely, Z. Hanzely, Z. Maherally, Z. Su   +312 more
core   +1 more source

Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms

Platelets, 2018
Essential thrombocythemia (ET) and polycythemia vera (PV) are myeloproliferative neoplasms (MPN) with an increased risk of arterial and venous thrombosis.
Andréas Perrier-Cornet, Jean-Christophe Ianotto, Fanny Mingant, Maëla Perrot, Eric Lippert, Hubert Galinat   +5 more
doaj   +1 more source

Clinical pictures of phenotypes of intolerance to aspirin and other nonsteroidal anti-inflammatory drugs. Part I

Pediatria i Medycyna Rodzinna, 2014
Clinically, three phenotypes of intolerance to aspirin and other nonsteroidal anti-inflammatory drugs are distinguished: bronchospastic phenotype, urticaria/oedema and chronic hyperplastic eosinophilic sinusitis.
Iwona Grzelewska-Rzymowska, Paweł Górski   +1 more
doaj   +1 more source

The targets of aspirin in bladder cancer: bioinformatics analysis

BMC Urology, 2022
Background The anti-carcinogenic properties of aspirin have been observed in some solid tumors. However, the molecular mechanism of therapeutic effects of aspirin on bladder cancer is still indistinct. We introduced a bioinformatics analysis approach, to
Xiao Li, Yanghao Tai, Shuying Liu, Yating Gao, Kaining Zhang, Jierong Yin, Huijuan Zhang, Xia Wang, Xiaofei Li, Dongfeng Zhang, Dong-feng Zhang   +10 more
doaj   +1 more source

The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study

BMC Cancer, 2021
Background Studies have indicated that individuals taking aspirin have a reduced risk of cancers and have also established chemo-preventive benefit of aspirin in colorectal cancer. However, research on the association between aspirin use and the survival
Min-Chun Chuang, Yao-Hsu Yang, Meng-Jer Hsieh, Yu-Ching Lin, Tsung-Ming Yang, Pau-Chung Chen, Ming-Szu Hung   +6 more
doaj   +1 more source

Application of low dose aspirin in pre-eclampsia

Frontiers in Medicine, 2023
Aspirin is widely used in the primary and secondary prevention of cardiovascular and cerebrovascular diseases. Low-dose aspirin is also widely used to prevent pre-eclampsia and fetal growth retardation in utero.
Yu Ren, Yong Zhao, Xiangdong Yang, Chaojun Shen, Hua Luo   +4 more
doaj   +1 more source

Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients

Journal of Translational Medicine, 2008
Background Our previous publication showed that 9% of patients with a history of myocardial infarction MI. could be labeled as aspirin resistant; all of these patients were aspirin resistant because of non-compliance.
Reeves Mathew, Barber Kimberly, Schwartz Dianne E, Schwartz Kenneth A, De Franco Anthony C   +4 more
doaj   +1 more source

In Silico screening of nonsteroidal anti-inflammatory drugs and their combined action on Prostaglandin H Synthase-1 [PDF]

, 2010
The detailed kinetic model of Prostaglandin H Synthase-1 (PGHS-1) was applied to in silico screening of dose-dependencies for the different types of nonsteroidal anti-inflammatory drugs (NSAIDs), such as: reversible/irreversible, nonselective/selective ...
Demin, Oleg, Goltsov, Alexey, Goltsov, Gregory, Goryanin, Igor, Humphery-Smith, Ian, Lebedeva, Galina   +5 more
core   +4 more sources

Impact of aspirin on bleeding and blood product usage in off‐pump and on‐pump coronary artery bypass graft surgery

eJHaem, 2022
Major bleeding is linked to poorer outcomes following cardiac surgery. Current guidelines recommend continuation of aspirin prior to coronary artery by‐pass graft (CABG) but the effect of continuing aspirin in patients with prior indication for aspirin ...
Christopher Little, Zain Odho, Richard Szydlo, Tuan‐Chen Aw, Mike Laffan, Deepa R. J. Arachchillage   +5 more
doaj   +1 more source